Journal of Neuromuscular Diseases Celebrates 10-Year Anniversary with Commemorative Editorial
The January 2024 edition of the Journal of Neuromuscular Diseases (JND) marked the journal’s 10-year anniversary! This is a special milestone for the publication that serves the international community as a publication for neuromuscular translational research, aiming to facilitate progress in understanding the molecular genetics/correlates, pathogenesis, pharmacology, diagnosis and treatment of acquired and genetic neuromuscular disease.
In recognition of this occasion, Co-Editors-in-Chief of the JND Dr. Hanns Lochmüller and Dr. Carsten Bonnëmann have published the editorial “The First Decade of Journal of Neuromuscular Diseases: Supporting and Advancing the Rapidly Evolving Field of Translational Research”, a review of the evolution of the JND from conception to current day.
Highlights from the editorial include:
- Remarks on the initial need for the journal
- Benchmarks of the journal’s impact and growth
- A content summary of JND publications by disease type, demographics, and research methodologies
- Discussion on recent trends, inspiration, and hope for the future of translational neuromuscular research
The entire team at the JND are proud to have been part of the past decade of exciting advancements in preclinical and clinical translational neuromuscular research, and look forward to another decade of growing the journal and serving the neuromuscular community.
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.